title: Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis?
authors.forename: E
authors.initials: E
authors.lastname: Wierzbicka
authors.forename: J M
authors.initials: JM
authors.lastname: Tourani
authors.forename: G
authors.initials: G
authors.lastname: Guillet
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases